Precision Approaches in Radiation Synthetic Combinations (PAIRS, RP1 Clinical Trial Optional)
Forecast
National Institutes of Health plans to offer grants to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. It is a forecast: the notice is expected around June 1, 2026, with applications due around November 11, 2026.
From the official notice on Grants.gov, last changed March 3, 2026. Checked October 31, 2026.
- Award ceilingnot stated
- Award floornot stated
- Expected awardsnot stated
- Total fundingnot stated
- Cost sharingNot required
- Funding typeGrant
Key dates
| Forecast posted | March 3, 2026 |
|---|---|
| Expected posting | June 1, 2026 |
| Expected deadline | November 11, 2026 |
| Expected award date | July 1, 2027 |
Add the deadline to your calendar
Who can apply
This opportunity is open to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses.
- State governments
- County governments
- City or township governments
- Special district governments
- Independent school districts
- Public and State controlled institutions of higher education
- Native American tribal governments (Federally recognized)
- Public housing authorities/Indian housing authorities
- Native American tribal organizations (other than Federally recognized tribal governments)
- Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
- Private institutions of higher education
- For profit organizations other than small businesses
- Small businesses
- Others (see text field entitled "Additional Information on Eligibility" for clarification)
Other Eligible ApplicantsIndian/Native American Tribal Governments (Other than Federally Recognized);Eligible Agencies of the Federal Government;U.S. Territory or Possession;Faith-based or Community-based Organizations;Regional Organizations;Non-domestic (non-U.S.) Entities (Foreign Institutions).
Is this a realistic fit?
- No cost sharing or match is required.
What the grant funds
Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) solicits research projects that investigate actionable synthetic vulnerabilities that can be conditionally paired with tumor responses to radiation therapy. The goal of the Precision Approaches in Radiation Synthetic Combinations (PAIRS) program is to develop radiation-synthetic combination strategies and facilitate their adoption into the precision medicine toolkit toward building new and effective anticancer treatments. Early synthetic lethality–based therapeutic strategies in oncology primarily focused on targeting fixed mutations or genomic abnormalities. More recently, however, it has become clear that clinical benefit is often determined by context-dependent vulnerabilities arising from the intrinsic mutational landscape and adaptive tumor responses. This NOFO is unique in its scope, supporting innovative cancer therapy strategies that explicitly exploit context-dependent effects of radiation therapy (RT) using drug-radiation combinations. The central premise of the PAIRS is that these conditional RT-induced responses can be leveraged to create or enhance actionable vulnerabilities that synergize with molecularly targeted agents for better outcomes. A defining feature of PAIRS is its emphasis on precision, scientific rigor, and reproducibility, aligned with NIH’s scientific priorities. Radiation effects are clinically titratable through advances in delivery accuracy and flexibility, including dose, schedule, and spatial targeting. These capabilities enable the rational design of conditional RT-synthetic combination strategies that preferentially exploit tumor-specific essentialities while sparing normal tissues, thereby enhancing the therapeutic index by optimizing biological response. This NOFO consolidates the prior exploratory/developmental and research project funding opportunities to streamline the application process and maintain momentum in developing approaches that target actionable vulnerabilities within the defined radiation research scope. The applicants may submit either for exploratory/developmental research projects with a project period of up to 2 years or for research projects with a project period of 4 to 5 years.
How to apply
- Read the full notice and attachments on Grants.gov. The notice is the official source for deadlines and requirements.
- Make sure your organization has an active SAM.gov registration and Unique Entity ID; registration can take several weeks.
- Register on Grants.gov and submit through Workspace before the deadline and time given in the notice. Our application guide walks through each step.
Questions go to NCI PAIRS Program, Telephone: 240-276-5703.
Questions people ask
Who can apply for Precision Approaches in Radiation Synthetic Combinations (PAIRS, RP1 Clinical Trial Optional)?
National Institutes of Health accepts applications from nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. The notice adds further conditions, so read its eligibility section.
What is the deadline for Precision Approaches in Radiation Synthetic Combinations (PAIRS, RP1 Clinical Trial Optional)?
Expected deadline November 11, 2026. Confirm the date and time in the official notice on Grants.gov.
Similar open grants
- Continuation of the Collaborative Islet Transplantation Registry (U01 Clinical Trial Not allowed)
- BRAIN Initiative Cell Atlas Network (BICAN): Coordinating Unit for Biostatistics, Informatics, and Engagement (CUBIE)
- Centers without Walls for mechanisms of neurodegeneration in Alzheimer’s disease-related dementias (ADRD)
- Expanding the Therapeutic Pipeline for Treating and Preventing Alzheimer's Disease and Related Dementias: Preclinical Validation and Drug Discovery for Novel Candidate Targets (U01 Clinical Trial Not Allowed)
- Systematic Testing of Radionuclides in Preclinical Experiments (STRIPE, RP1 Clinical Trial Not Allowed)
- Exposomic Contributions to ADRD Pathology and Resilience